目的 评估苏合香丸与单硝酸异山梨酯联合治疗方案对冠心病稳定型心绞痛患者的临床效果。方法 选自2024年1月—12月郑州市第七人民医院收治的80例冠心病稳定型心绞痛患者，按照随机数字表法分成对照组和治疗组，各40例。对照组口服单硝酸异山梨酯缓释胶囊，40 mg/次，1次/d。治疗组患者在对照组方案基础上口服苏合香丸，1丸/次，2次/d。两组均治疗4周。观察两组的治疗效果和心绞痛发作情况，比较两组治疗前后射血分数（EF）、每搏量（SV）、心电图参数（QRS间期、QTc间期）、收缩期峰流速（SPV）、舒张期峰流速（DPV）及冠脉血流储备（CFR）、西雅图心绞痛量表（SAQ）评分。结果 治疗后，治疗组总有效率（97.50%）显著高于对照组（75.00%）（P＜0.05）。治疗后，两组心绞痛发作次数显著减少，单次发作持续时间显著缩短（P＜0.05）；治疗后，治疗组心绞痛发作次数少于对照组，单次发作持续时间短于对照组（P＜0.05）。治疗后，两组SV、EF值均较同组治疗前显著提高，QRS间期、QTc间期较前缩短（（P＜0.05）；治疗后，治疗组SV、EF高于对照组，QRS间期、QTc间期短于对照组（P＜0.05）。治疗后，两组SPV、DPV、CFR较同组治疗前均显著提高（P＜0.05）；治疗后治疗组SPV、DPV、CFR高于对照组（P＜0.05）。治疗后，两组躯体活动受限程度评分、心绞痛稳定状态评分、心绞痛发作频率评分均较同组治疗前显著提高（P＜0.05）；治疗后治疗组上述维度评分高于对照组（P＜0.05）。结论 苏合香丸联合单硝酸异山梨酯有利于提高冠心病稳定型心绞痛的治疗效果，有利于改善患者心功能，减少心绞痛发作，提升生活质量，提高患者临床获益。

Objective To evaluate the clinical efficacy of the combined treatment regimen of Suhexiang Pills and isosorbide mononitrate in patients with stable angina pectoris of coronary heart disease. Methods Patients (80 cases) with stable angina pectoris of coronary heart disease who were admitted to Zhengzhou Seventh People’s Hospital from January 2024 to December were divided into control group and treatment group according to random number table method, with 40 cases in each group. Patients in control group were po administered with Isosorbide Mononitrate Sustained-release Capsules, 40 mg/time, once daily. Patients in treatment group were po administered with Suhexiang Pills on the basis of the control group, 1 pill each time, twice daily. Both groups were treated for 4 weeks. The therapeutic effects and angina pectoris attack situations of two groups were observed, and the EF, SV, electrocardiogram parameters (QRS interval, QTc interval), SPV, DPV, CFR, and SAQ score before and after treatment were compared between two groups. Results After treatment, the total effective rate of the treatment group (97.50%) was significantly higher than that of the control group, (75.00%) (P < 0.05). After treatment, the number of angina pectoris attacks in both groups significantly decreased, and the duration of each attack significantly shortened (P < 0.05). After the treatment, the number of angina pectoris attacks in treatment group was less than that in control group, and the duration of each attack was shorter than that in control group (P < 0.05). After treatment, the SV and EF values of both groups were significantly higher than those before treatment in the same group, but the QRS interval and QTc interval were shorter (P < 0.05). After treatment, the SV and EF of treatment group were higher than those of control group, but the QRS interval and QTc interval were shorter than those of control group (P < 0.05). After treatment, the SPV, DPV, and CFR of both groups were significantly higher than those before treatment in the same group (P < 0.05). After treatment, the SPV, DPV, and CFR of treatment group were higher than those of control group (P < 0.05). After treatment, the scores of physical activity limitation, stable angina pectoris status, and angina pectoris attack frequency in both groups were significantly higher than those before treatment in the same group (P < 0.05). After treatment, the scores of the above dimensions in treatment group were higher than those of control group (P < 0.05). Conclusion Suhexiang Pills combined with isosorbide mononitrate is beneficial for enhancing the therapeutic effect of stable angina pectoris in coronary heart disease, improving the patients’ cardiac function, reducing the occurrence of angina pectoris, enhancing the quality of life, and increasing the clinical benefits of the patients.

R972

河南省医学科技攻关计划项目（LH-GJ20210752）